BitGo has introduced Bitcoin staking for qualified custody clients through a partnership with Stacks. This allows eligible clients to stake Bitcoin held in BitGo Bank & Trust custody and earn rewards in BTC. The staking rewards are funded by the BTC spent by Stacks miners to produce blocks. Previously, BitGo partnered with HashKey Cloud for staking on Ethereum and Solana networks, expanding its staking services.
BitGo's launch of Bitcoin staking for qualified custody clients provides context for cryptocurrency market activity. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Nov 04, 2026 10:01 WIB: out of 50 major cryptocurrencies priced on Pluang, 14 rose and 35 fell today. Notable movers include BCH (Bitcoin Cash) at Rp4.851.394 with a 1-day change of -2.66% and a typical hold time of 69 days, ZIL (Zilliqa) at Rp31 down 2.58%, and FIL (Filecoin) at Rp15.334 down 2.29%.
Milestone Pharmaceuticals announced the grant of 33,000 stock options to a newly hired employee as an inducement under Nasdaq Listing Rule 5635(c)(4). The options, priced at $0.72 each, will vest over four years with a one-year cliff and monthly inst...
Zcash (ZEC) saw its price fall 3.58% over a four-hour period to $1,184 on Binance's spot ZEC/USDT pair, despite a 4.04% gain over the past 24 hours. During a one-hour window, liquidations of ZEC positions across Binance, Bybit, and OKX totaled $380,0...
The xZEC token has been launched on the Solana blockchain through the Hylo platform, marking its entry into a new network for digital assets and applications. Hylo, known for developing leveraged tokens and the decentralized stablecoin hyUSD on Solan...
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
Delcath Systems, a small-cap healthcare equipment company, is expected to announce strong Q3 results on November 9, with a high chance of beating revenue estimates. The company’s recent success in the CHOPIN phase II trial and expansion of treatment ...
